# CREATE Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/create-medicines

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.createmedicines.com
- Total disclosed funding: $122M
- Latest round: Series B (May 14, 2026)
- Investors on record: 4

## About

Based in the US, CREATE Medicines, Inc. specializes in advanced immunotherapy solutions, utilizing innovative CAR therapies to program immune responses against various diseases, particularly in oncology and autoimmunity.CREATE Medicines, Inc. was founded in 2019 and is headquartered in Cambridge, US. The company focuses on developing advanced immunotherapy solutions through its proprietary in vivo CAR platform. It raised USD 122.00 mn in its latest funding round, Series B, involving investors such as ARCH Venture Partners and Alexandria Venture Investments. The total amount raised to date is also USD 122.00 mn, indicating a strong backing from prominent investors.CREATE Medicines specializes in advanced immunotherapy solutions, focusing on multi-immune programming through its proprietary in vivo CAR (Chimeric Antigen Receptor) platform. The core product offerings include a suite of mRNA-LNP (lipid nanoparticle) CAR therapies that facilitate direct programming of immune cells, specifically T cells, NK cells, and myeloid cells, within the body. These therapies are aimed at addressing medical challenges in oncology, autoimmunity, and fibrosis, with a focus on overcoming barriers associated with solid tumors. Recent developments indicate potential for widespread application in treating traditionally untreatable diseases, with the company targeting markets in North America and Europe, primarily engaging hospitals, research institutes, and clinical trial networks.CREATE Medicines generates revenue through partnerships, clinical collaborations, and direct engagements with healthcare providers. The transactional model revolves around providing in vivo CAR therapies to clinical trial participants and healthcare partners, which may include customized treatment plans. The company's flagship products, such as MT-304 targeting HER2-positive solid tumors, are expected to generate significant interest within the oncology sector, enabling revenue generation through licensing agreements and collaborative research initiatives.CREATE Medicines intends to utilize the recent funding from the Series B round to support the development of new products, particularly in advancing its mRNA-LNP CAR therapies. The company is focusing on expanding its reach into North American and European markets, aiming to enhance collaborations with hospitals and research institutions by the end of 2024. The funding will facilitate the execution of these growth strategies, enhancing CREATE's capacity to contribute to innovative therapeutic solutions.

## Funding rounds

- Series B, May 14, 2026, $122M — ARCH Venture Partners, Alexandria Venture Investments, Hatteras Venture Partners, Newpath Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series B
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series B